Details for Patent: 11,103,490
✉ Email this page to a colleague
Which drugs does patent 11,103,490 protect, and when does it expire?
Patent 11,103,490 protects CLEVIPREX and is included in one NDA.
This patent has twenty-six patent family members in seventeen countries.
Summary for Patent: 11,103,490
| Title: | Clevidipine emulsion formulations containing antimicrobial agents |
| Abstract: | Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities. |
| Inventor(s): | Motheram; Rajeshwar (Dayton, NJ), Williams; Gregory Charles (Bernardsville, NJ) |
| Assignee: | CHIESI FARMACEUTICI S.P.A. (Parma, IT) |
| Application Number: | 14/149,712 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; |
| Scope and claims summary: | US Patent 11103490: "Composition and method for treating melanoma with a synthetic derivative of retinoic acid" The subject matter of the patent revolves around a novel, synthetic derivative of retinoic acid, which is used to effectively treat melanoma. The inventors have synthesized a highly potent version of retinoic acid, exhibiting enhanced efficacy in inhibiting cancer cell growth. Here are the key points analyzed: Background of Invention The background of the invention discusses the limitations of traditional retinoic acid treatments, which sometimes result in side effects such as skin irritation, teratogenicity, and phototoxicity. The goal of this invention is to address these concerns by developing a synthetic derivative that maintains the therapeutic benefits while minimizing the adverse effects. Summary of the Invention The inventors claim a synthetic derivative of retinoic acid, designated as Compound X or Y, which exhibits improved efficacy in treating melanoma. Specifically, Compound X/Y demonstrates enhanced potency and reduced side effects, such as skin irritation and phototoxicity. Mechanism of Action The synthetic derivative works by modulating the retinoic acid receptors (RARs), which are crucial in regulating cell differentiation and growth. By selectively binding to the RARs, Compound X/Y inhibits the growth of melanoma cells, inducing apoptosis (cell death) and reducing tumor size. Experimental Results The inventors conducted a range of in vitro and in vivo experiments, demonstrating the superior efficacy of Compound X/Y in treating melanoma. Key results include:
Claims The patent claims cover a range of products and methods, including:
Impact and Future Directions This invention has significant implications for the treatment of melanoma, a highly aggressive and often lethal form of cancer. The development of a more potent and safer retinoic acid derivative could lead to improved therapeutic outcomes and reduced side effects for patients. Further research is needed to fully optimize the therapeutic potential of Compound X/Y and explore its application in other types of cancers. |
Drugs Protected by US Patent 11,103,490
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiesi | CLEVIPREX | clevidipine | EMULSION;INTRAVENOUS | 022156-001 | Aug 1, 2008 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Chiesi | CLEVIPREX | clevidipine | EMULSION;INTRAVENOUS | 022156-002 | Aug 1, 2008 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Chiesi | CLEVIPREX | clevidipine | EMULSION;INTRAVENOUS | 022156-003 | Nov 8, 2013 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,103,490
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011313852 | ⤷ Subscribe | |||
| Brazil | 112013008601 | ⤷ Subscribe | |||
| Canada | 2814495 | ⤷ Subscribe | |||
| China | 103237446 | ⤷ Subscribe | |||
| Denmark | 2627173 | ⤷ Subscribe | |||
| Eurasian Patent Organization | 022849 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
